|
|
eculizumab A human monoclonal antibody directed against terminal complement protein C5. Eculizumab binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and blocking the complement-mediated destruction of paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Synonyms: | | Alexion monoclonal antibody 5G1.1 monoclonal antibody anti-C5 | | | US brand name: | | Soliris | | | Abbreviation: | | h5G1.1 | | |
|
|